报道指港交所(00388.HK)已筹建新股平台「FiNI」 加快新股上市
《信报》报道,港交所(00388.HK)已筹建名为「FiNI」的平台,集中处理股份发行及结算交收等事宜,并精简现行新股发行相关的手续,以加快整个新股发行流程,缩短新股由定价到上市间的周期。港交所发言人回应报道指,正研究缩短现有新股交收流程的方法,为其持续提升新股市场竞争力工作的一部分,将於有具体建议方案时向市场公布。
报道引述知识产权署资料显示,港交所於6月时已申请注册「FiNI」商标,并已筹备一段时间,惟暂时仍未有正式推出的确实时间表,平保(02318.HK)旗下的平安科技亦有份协助筹建「FiNI」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.